Last reviewed · How we verify

Trumenba — Competitive Intelligence Brief

Trumenba (trumenba) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains. Area: Infectious Disease.

preclinical Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains Infectious Disease Vaccine Live · refreshed every 30 min

Target snapshot

Trumenba (trumenba) — Pfizer Inc.. Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trumenba TARGET trumenba Pfizer Inc. preclinical Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trumenba — Competitive Intelligence Brief. https://druglandscape.com/ci/trumenba. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing